Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 57Stomach Neoplasms 45Carcinoma, Non-Small-Cell Lung 36Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Lung Neoplasms 11Esophageal Neoplasms 11Nasopharyngeal Carcinoma 10Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Liver Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Solid Tumor 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3

Interventions

S 1 (combination) 2tislelizumab 1sintilimab 1Paclitaxel 1Hyperthermic Intraperitoneal Chemotherapy 1Doxorubicin 1Cisplatin 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastric Cancer Peritoneal Metastases × sintilimab × Clear all
NCT06487715 2024-07-05

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
42 enrolled
Gastrointestinal

Gastric Cancer Peritoneal Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡